Cart
sales@molnova.com
GSK-2838232
CAS No. 1443460-91-0
GSK-2838232( GSK2838232 )
Catalog No. M11882 CAS No. 1443460-91-0
GSK-2838232 is a novel HIV maturation inhibitor being developed for the treatment of HIV in combination with other antiretroviral therapy.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 187 | In Stock |
|
| 5MG | 132 | In Stock |
|
| 10MG | 211 | In Stock |
|
| 25MG | 464 | In Stock |
|
| 50MG | 662 | In Stock |
|
| 100MG | 918 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK-2838232
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-2838232 is a novel HIV maturation inhibitor being developed for the treatment of HIV in combination with other antiretroviral therapy.
-
DescriptionGSK-2838232 is a novel HIV maturation inhibitor being developed for the treatment of HIV in combination with other antiretroviral therapy.HIV Infection Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsGSK2838232
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research AreaInfection
-
IndicationHIV Infection
Chemical Information
-
CAS Number1443460-91-0
-
Formula Weight809.57
-
Molecular FormulaC48H73ClN2O6
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 50 mg/mL 61.76 mM
-
SMILESO=C(O)C(C)(C)CC(O[C@@H](CC[C@]1(C)[C@@]2([H])CC[C@@]34[H])C(C)(C)[C@]1([H])CC[C@@]2(C)[C@]3(C)CC[C@]5([C@@H](O)CN(CC6=CC=CC(Cl)=C6)CCN(C)C)C4=C(C(C)C)C(C5)=O)=O
-
Chemical Name(3b)-3-(3-Carboxy-3-methyl-1-oxobutoxy)-17-[(1R)-2-[[(4-chlorophenyl)methyl][2-(dimethylamino)ethyl]amino]-1-hydroxyethyl]-28-norlup-18-en-21-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
GRL-079
GRL-079 is a novel potent, nonpeptidic HIV-1 protease inhibitor with 2.5-30 nM.
-
GS-6207
GS-6207 (GS6207, GS-CA1) is a potent, selective inhibitor of HIV-1 capsid function with potency and potential to be clinically effective against a broad range of HIV-1 strains.
-
DAPTA
DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities. DAPTA potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5.
